THE STEAM-JET AEROSOL COLLECTOR

A new principle of sampling aerosol particles by means of steam injection with the consequent collection of grown droplets has been established. An air stream free of water-soluble gases is rapidly mixed with steam. The resulting supersaturation causes aerosol particles to grow into droplets. The droplets containing dissolved aerosol species are then collected by two cyclones in series. The solution collected in the cyclones is constantly pumped out and can be on- or off-line analysed by means of ion chromatography or flow injection analysis. On the basis of the new sampling principle a prototype of an aerosol sampler was designed which is capable of sampling particles quantitatively down to several nanometres in diameter. The mass sampling efficiency of the instrument was found to be 99\%. The detection limit of the sampler for ammonium, sulphate, nitrate and chloride ions is below 0.7 mu g m(-3). By reduction of an already identified source of contamination, much lower detection limits can be achieved. During measurements the sampler proved to be stable, working without any assistance for extended periods of time. Comparison of the sampler with filter packs during measurements of ambient air aerosols showed that the sampler gives good results.

A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

PURPOSE: Cutaneous sclerosis occurs in 20% of patients with chronic graft-versus-host disease (GVHD) and can compromise mobility and quality of life. EXPERIMENTAL DESIGN: We conducted a prospective, multicenter, randomized, two-arm phase II crossover trial of imatinib (200 mg daily) or rituximab (375 mg/m(2) i.v. weekly × 4 doses, repeatable after 3 months) for treatment of cutaneous sclerosis diagnosed within 18 months (NCT01309997). The primary endpoint was significant clinical response (SCR) at 6 months, defined as quantitative improvement in skin sclerosis or joint range of motion. Treatment success was defined as SCR at 6 months without crossover, recurrent malignancy or death. Secondary endpoints included changes of B-cell profiles in blood (BAFF levels and cellular subsets), patient-reported outcomes, and histopathology between responders and nonresponders with each therapy. RESULTS: SCR was observed in 9 of 35 [26%; 95% confidence interval (CI); 13%-43%] participants randomized to imatinib and 10 of 37 (27%; 95% CI, 14%-44%) randomized to rituximab. Six (17%; 95% CI, 7%-34%) patients in the imatinib arm and 5 (14%; 95% CI, 5%-29%) in the rituximab arm had treatment success. Higher percentages of activated B cells (CD27(+)) were seen at enrollment in rituximab-treated patients who had treatment success (P = 0.01), but not in imatinib-treated patients. CONCLUSIONS: These results support the need for more effective therapies for cutaneous sclerosis and suggest that activated B cells define a subgroup of patients with cutaneous sclerosis who are more likely to respond to rituximab.